GRI Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:GRI Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014146
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GRI Bio Inc (GRI Bio) is a biotech company that develops and manufactures therapies for inflammatory diseases. The company develops Natural Killer T cell based therapies for the treatment of liver disease and autoimmune disoders. Its lead candidate GRI-0621, a novel oral therapeutic for liver disease is an inhibitor of type I NKT cells. GRI Bio’s other pipeline products include GRI 101, GRI-0621, GRI 201, GRI 202 and GRI 203 are under preclinical stage of development for the treatment of chronic liver disease and ALD. Its research and development facility is located at the Torrey Pines Institute of Molecular Studies. GRI Bio is headquartered in La Jolla, California, the US.

GRI Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
GRI Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
GRI Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
GRI Bio Acquires Type 1 NKT cell Technology Rights from Torrey Pines Institute 10
Venture Financing 11
Glycoregimmune Raises USD4.4 Million in Venture Financing 11
GRI Bio Raises USD0.2 Million in Seed Financing 12
Partnerships 13
RxMD Enters Into Collaboration Agreement With GlycoRegImmune 13
GRI Bio Inc – Key Competitors 14
GRI Bio Inc – Key Employees 15
GRI Bio Inc – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
GRI Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
GRI Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
GRI Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
GRI Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
GRI Bio Acquires Type 1 NKT cell Technology Rights from Torrey Pines Institute 10
Glycoregimmune Raises USD4.4 Million in Venture Financing 11
GRI Bio Raises USD0.2 Million in Seed Financing 12
RxMD Enters Into Collaboration Agreement With GlycoRegImmune 13
GRI Bio Inc, Key Competitors 14
GRI Bio Inc, Key Employees 15

★海外企業調査レポート[GRI Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Waters Corporation (WAT):医療機器:M&Aディール及び事業提携情報
    Summary Waters Corporation (Waters) is an analytical instrument manufacturing company. It carries out the design, production, commercialization and servicing of analytical technologies such as high performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), chromatograp …
  • Day & Zimmermann Group, Inc.:企業の戦略・SWOT・財務分析
    Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Plug Power Inc (PLUG):企業の財務・戦略的SWOT分析
    Summary Plug Power Inc (Plug Power) is an alternative energy company that designs and develops fuel cell structures. The company’s products comprise gendrive, genkey, material handling products, gensure, genfuel and genfuel for stationary markets products. Its material handling products comprise out …
  • Century Casinos Inc:戦略・SWOT・企業財務分析
    Century Casinos Inc - Strategy, SWOT and Corporate Finance Report Summary Century Casinos Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Emerson Radio Corporation (MSN):企業の財務・戦略的SWOT分析
    Emerson Radio Corporation (MSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Drake & Scull International (DSI):企業の財務・戦略的SWOT分析
    Drake & Scull International (DSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • ENAMINE Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Enamine Ltd (Enamine) is a provider of screening and drug discovery services. The company’s products include building blocks and intermediates, screening compounds, real database, compound libraries, fragment library, tangible building blocks, materials chemistry and scaffolds. It offers ser …
  • TripAdvisor Inc:企業の戦略・SWOT・財務分析
    TripAdvisor Inc - Strategy, SWOT and Corporate Finance Report Summary TripAdvisor Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Topas Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Topas Therapeutics GmbH (Topas Therapeutics) is a biotechnological company that designs and develops nanoparticle products loaded with antigenic peptides. The company’s pre-clinical pipeline categories are used in the treatment of allergies, immune mediated diseases, autoimmune diseases, and …
  • Northern Vertex Mining Corp:企業の戦略・SWOT・財務分析
    Northern Vertex Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Northern Vertex Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • RPS Group Plc (RPS):企業の財務・戦略的SWOT分析
    RPS Group Plc (RPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Blueprint Medicines Corp (BPMC):企業の財務・戦略的SWOT分析
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralse …
  • K-Electric Ltd (KEL):企業の財務・戦略的SWOT分析
    K-Electric Ltd (KEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Labco SA-製薬・医療分野:企業M&A・提携分析
    Summary Labco SA (Labco) is a medical diagnostic company that provides clinical laboratory services. The company provides detection and prevention of chronic and severe disorders. Its medical services include laboratory, internal analysis and transmission of internal results and diagnostic interpret …
  • Valero Energy Corporation (VLO)-石油・ガス分野:企業M&A・提携分析
    Summary Valero Energy Corporation (Valero) is a manufacturer and marketer of transportation fuels, petrochemical products and power. The company’s assets include petroleum refineries, ethanol plants, a wind farm and renewable diesel production from a joint venture. Its refineries produce gasoline, d …
  • Sandvik AB:企業の戦略・SWOT・財務情報
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • European Medical Contract Manufacturing BV:医療機器:M&Aディール及び事業提携情報
    Summary European Medical Contract Manufacturing BV (EMCM BV), a subsidiary of Leader Biomedical Group, is a developer and manufacturer of sterile medicinal products. The company’s products include bone cements for hip and knee arthroplasty and vertebroplasty procedures; cement restrictors; human bon …
  • Xtant Medical Holdings Inc (XTNT)-製薬・医療分野:企業M&A・提携分析
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings, Inc. is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteow …
  • Veritas (India) Ltd:企業の戦略・SWOT・財務情報
    Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆